(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 4.81% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Amphastar Pharmaceuticals's revenue in 2026 is $720,530,000.On average, 9 Wall Street analysts forecast AMPH's revenue for 2026 to be $33,455,943,220, with the lowest AMPH revenue forecast at $31,570,089,075, and the highest AMPH revenue forecast at $34,954,661,537. On average, 9 Wall Street analysts forecast AMPH's revenue for 2027 to be $35,025,210,208, with the lowest AMPH revenue forecast at $32,511,913,825, and the highest AMPH revenue forecast at $37,579,953,935.
In 2028, AMPH is forecast to generate $36,569,785,160 in revenue, with the lowest revenue forecast at $33,402,149,859 and the highest revenue forecast at $39,584,418,032.